XVIVO appoints a new IP manager and a new Medical Director

Anne-Li Sigvardsson, MSc has been appointed Chief Intellectual Property Officer (CIPO). Anne-Li is responsible for the company's IP portfolio and has developed XVIVO's patent portfolio for PrimECC and Perfadex Plus, among other products. Andreas Wallinder, MD, PhD has been appointed Chief Medical Officer (CMO). Andreas is the indication leader for the company's heart preservation development and also clinically responsible within the company.

Anne-Li Sigvardsson has a MSc in chemical engineering and has worked with research and development in the medical technology field for more than 20 years, and with XVIVO products since 2004. Previously, she has also worked with global marketing and sales, an experience that gave a good understanding for developing intellectual property that is relevant and useful in the market. Anne-Li is responsible for the company's IP portfolio.

Andreas Wallinder has been employed at XVIVO for 6 months. He specialized in thoracic surgery and has performed research and his PhD in the field of EVLP (Ex Vivo Lung Perfusion) and lung transplantation. During his 16 years at Sahlgrenska University Hospital, as well as Alfred Health in Melbourne, Andreas has performed both lung transplants and heart transplants. Andreas is the indication leader for the company's heart preservation development and also clinically responsible within the company.

“One of XVIVO's strategic cornerstones is to recruit employees with high competence, an innovation mindset and strong a faith in the company's vision – that no one should die waiting for an organ. These employees are another two very good examples of this and I am proud that we can continue to attract and retain highly qualified employees.," says Magnus Nilsson, CEO of XVIVO Perfusion.

                                                                                                                                 

April 24, 2020

Gothenburg

XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication, through the agency of the contact person set out above, at 3:40 am CET on April 24, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.